IMPROVE-IT

[Anonymous]

This is a great example of why you don't rely on CP-especially from merck employees-for accurate news. IMPROVE-IT hit its endpoint. Not sure how it will all play out but its great news for the company-despite how the company continues to be managed. But its obvious that nobody in the sales force is pumped to work for merck based on the past 10 years of behavior. Its been so negative. We'll see how this chapter plays out. Merck reps are too negative-and for understandably good reasons. Not sure much will change with the current leadership in place.

If you think IMPROVE-IT hit its endpoint, you are delusional.

 

[Anonymous]

Lipitor better.

Crestor still the best.

 

[Anonymous]

So LDL lowering will be the end game?

Yes , just like I told you last week. It is all about the reduction in ldl. Ezetimibe added on to a statin gives an imcremental benefit. " The results today are positive for Merck’s Zetia and Vytorin but go beyond by suggesting that LDL lowering with drugs other than statins provides a cardiovascular benefit (a reaffirming of the LDL hypothesis that was beginning to be questioned) and that LDL levels should possibly be driven lower than guidelines have recommended (below 70 mg/dl). Today’s results add the first real data point to our understanding of the relationship between LDL reduction and outcomes at very low LDL levels…"

 

[Anonymous]

If you think IMPROVE-IT hit its endpoint, you are delusional.[/QUOTE

Yeah- me and all the investigators, the physicians, Wall Street and all those reporting it

Cheesedick